Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-05-28 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG
Foreign Filer Report
2021-05-28 English
Tagrisso approved in EU in early lung cancer
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated May 28, 2021. It announces a significant regulatory event: the approval of the drug Tagrisso in the European Union for a specific cancer treatment. The content is a press release detailing clinical trial results and business impact, typical of a major corporate announcement disseminated via a regulatory news service. Since it is a formal announcement of a material event (drug approval) distributed through the RNS system, and it is not a full financial report (like 10-K or IR), nor a transcript, nor a proxy statement, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official, non-standardized announcements. It is not an Earnings Release (ER) as it focuses on regulatory approval, not financial results. It is not an Earnings Call Transcript (CT). It is not a Report Publication Announcement (RPA) because it contains the substantive news itself, not just a notice that a report is available.
2021-05-28 English
424B2
Prospectus
2021-05-27 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1928 chars) and contains the header 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific, time-sensitive regulatory market announcement. This type of general regulatory announcement that doesn't fit into the specific financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2021-05-27 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1911 characters) and contains the header 'RNS Number'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, which is approved as a Primary Information Provider. This is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K, ER, or IR. Therefore, it falls under the general regulatory announcement category.
2021-05-27 English
ASTRAZENECA PRICES A EUR800M BOND OFFERING
Foreign Filer Report
2021-05-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.